Histopathological evaluations of animal and human tissues are an integral part of business decisions in drug development, especially early in the discovery process, when key decisions are made at small biotech companies or in large pharmaceutical discovery groups for prioritization of good laboratory practice (GLP) preclinical testing.
Flagship’s pathologists have over 60 years of combined experience in pharmaceutical drug development, and can assist development efforts to better characterize efficacy and to help identify potential drug candidates early in the discovery process. We also have expertise in directing early pilot studies, and in developing protocols for subsequent quantitative image analysis studies. We utilize both manual descriptive pathology evaluation as well as ground-breaking new techniques in whole slide analysis in assessing the full spectrum of compound effect
The important of involving pathologists early in the development process is detailed in a recent article in Drug Discovery Today.